17ß-Estradiol/Dydrogesterone
Drug1/5 mg/day for 12 cycles of 28 days
NCT Number: NCT00145522
This study is to evaluate the effects of continuously combined 17b-estradiol/dydrogesterone in comparison with tibolone on the breast metabolic markers, in particular the total insulin-like growth factor-1 (IGF-1), in postmenopausal women.
Looking for future studies?
Notify Me45 year–65 year
Female
Interventional
Phase 4
Site 8, Ancona, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1/5 mg/day for 12 cycles of 28 days
2,5 mg/day for 12 cycles of 28 days
Time frame: 1 year
Time frame: 1 year
Looking for future studies?
Notify MeSolvay Pharmaceuticals
Industry
A Twelve 28-Day Cycles, Multicenter, Prospective, Randomized, Open, Blinded Endpoint, Parallel Group Study Comparing the Effect on Breast and Cardiovascular Metabolic Markers of Continuously Combined 17β-Estradiol/Dydrogesterone and Tibolone in Postmenopausal Women.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07824947
Behavior, Female Urogenital Diseases
Madrid, Villaviciosa de ODON, Spain
View Trial DetailsNCT07044284
Menopause
London, United Kingdom
View Trial DetailsNCT07757724
Dyssomnias, Menopause
Macao, Macau
View Trial DetailsNCT07771946
Blindness, Eye Diseases
Ankara, Altindağ, Turkey (Türkiye)
View Trial Details